Migraine is a recurrent neurological disorder characterized by severe headaches, often accompanied by nausea, vomiting, photophobia, and phonophobia. Affecting approximately 15–20% of the global population, migraine is more prevalent in women and is a leading cause of disability worldwide. The disorder is multifactorial, involving genetic predisposition, neurotransmitter dysregulation, trigeminovascular system activation, and vascular changes in the brain.

This article reviews the etiology, pathophysiology, and current treatment strategies for migraine. Acute attacks are managed using abortive therapies, such as triptans and nonsteroidal anti-inflammatory drugs (NSAIDs), while prophylactic therapy—including beta-blockers, anticonvulsants, calcium channel blockers, and CGRP inhibitors—aims to reduce attack frequency and severity. Lifestyle modifications, stress management, and complementary interventions further enhance treatment efficacy.

Recent research incorporating neuroimaging, genetic analysis, and clinical monitoring has advanced understanding of migraine mechanisms and enabled individualized treatment approaches. Biomarkers and patient response monitoring improve therapeutic outcomes and reduce complications. Integration of pharmacological and non-pharmacological strategies enhances patient quality of life and reduces disease burden.

This review emphasizes the importance of understanding migraine pathophysiology, clinical manifestations, and treatment strategies. A multidisciplinary approach combining modern pharmacotherapy, preventive strategies, and lifestyle modifications is essential for effective migraine management.

Migraine, Headache, Neurological disorder, Trigeminovascular system, Genetic predisposition, Triptans, Prophylactic therapy, Neurotransmitters, Abortive treatment, Lifestyle modification

Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211.

Stovner LJ, Andrée C. Prevalence of headache in Europe: a review for the Eurolight project. J Headache Pain. 2010;11(4):289–299.

Lipton RB, Bigal ME. Migraine: epidemiology, impact, and risk factors for progression. Headache. 2005;45(Suppl 1):S3–S13.

Charles A. The pathophysiology of migraine: implications for clinical management. Lancet Neurol. 2018;17(2):174–182.

Buse DC, Manack AN, Fanning KM, et al. Chronic migraine prevalence, disability, and sociodemographic factors: results from the American Migraine Prevalence and Prevention Study. Headache. 2012;52(10):1456–1470.

Ferrari MD, Goadsby PJ. Migraine genetics and pathophysiology: implications for therapy. Curr Opin Neurol. 2006;19(3):277–284.

Goadsby PJ, Holland PR, Martins-Oliveira M, et al. Pathophysiology of migraine: a disorder of sensory processing. Physiol Rev. 2017;97(2):553–622.

Edvinsson L. The trigeminovascular pathway: role of CGRP and CGRP receptors in migraine. Headache. 2017;57(Suppl 2):47–55.

Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a review of pharmacology and clinical efficacy. Cephalalgia. 2000;20(3):195–208.

Silberstein SD. Preventive migraine treatment. Neurol Clin. 2015;33(2):345–367.

Schwedt TJ, Dodick DW. Advanced neuroimaging of migraine. Lancet Neurol. 2009;8(6):560–568.

Diener HC, Charles A, Goadsby PJ, Holle D. New therapeutic approaches for the prevention and treatment of migraine. Lancet Neurol. 2015;14(10):1010–1022.